SLS: רווח נקי למניה (EPS TTM) SELLAS Life Sciences

SELLAS Life Sciences (SLS) ensures high-precision transport of biosamples, minimizing cargo spoilage and maintaining profitability. The TTM net income per share distribution demonstrates capital dynamics, where -0.21 reflects the latest metric value. The company develops vaccines based on GPS technology to combat relapses, although its survival depends on the results of Phase 3 trials amid critically low cash reserves.

For SELLAS Life Sciences (SLS), which integrates AI into oncology drug development, the rolling net income per share reflects the efficiency of capitalizing scientific achievements. The current value of -0.21 is calculated as the ratio of total annual net income to the number of common shares, allowing investors to filter out price noise and assess the real fundamental value of the business relative to industry peers.